» Articles » PMID: 37702056

Risk Factors and Outcomes With Progressive Mitral Annular Calcification

Overview
Date 2023 Sep 13
PMID 37702056
Authors
Affiliations
Soon will be listed here.
Abstract

Background Mitral annular calcification (MAC) is a chronic degenerative process that may progress. This study aimed to investigate associating factors and clinical implications of MAC progression. Methods and Results Among 560 patients with MAC identified by transthoracic echocardiography between January 2012 and June 2016, 138 patients (mean±SD age 72.7±10.2 years, 73 women) with mild or moderate MAC who received follow-up examination within 18 to 36 months were retrospectively analyzed. Progressive MAC was defined as hemodynamic or structural profiles that had worsened by more than 1 grade. Hemodynamic features were assessed by the transmitral mean diastolic pressure gradient (MDPG), and structural features were assessed by the MAC angle in the parasternal short-axis view. The clinical outcome was defined as a composite of all-cause mortality, hospitalization for heart failure, and occurrence of ischemic stroke. Forty-three patients (31.2%) showed progressive MAC. Patients with progressive MAC had higher systolic blood pressure, pulse pressure, MAC angle, and MDPG than those with stable MAC. Patients with progressive MAC had smaller left ventricular (LV) end-systolic dimensions and higher LV ejection fractions compared with those with stable MAC. In multivariate analysis, pulse pressure, LV ejection fraction, MAC angle, and MDPG at baseline were significantly associated with MAC progression. During a median of 39.2 months' follow-up, patients with progressive MAC showed poorer clinical outcomes than those with stable MAC (log-rank =0.015). Conclusions MAC progression is not rare and is associated with structural substrate and hemodynamic loads that result in mechanical stress. Patients with progressive MAC have poor outcomes.

Citing Articles

Contemporary diagnosis and treatment of valvular heart disease in Korea: a nationwide hospital-based registry study.

Kim H, Lee H, Kim I, Son J, Park J, Lee S J Cardiovasc Imaging. 2024; 32(1):37.

PMID: 39574207 PMC: 11583530. DOI: 10.1186/s44348-024-00036-z.


Rethinking Mitral Annular Calcification and Its Clinical Significance: From Passive Process to Active Pathology.

Morariu P, Oancea A, Gosav E, Buliga-Finis O, Cuciureanu M, Scripcariu D J Pers Med. 2024; 14(9).

PMID: 39338154 PMC: 11433102. DOI: 10.3390/jpm14090900.


Mitral Annular Calcification-Related Valvular Disease: A Challenging Entity.

Museedi A, Le Jemtel T J Clin Med. 2024; 13(3).

PMID: 38337590 PMC: 10856114. DOI: 10.3390/jcm13030896.

References
1.
Otto C, Nishimura R, Bonow R, Carabello B, Erwin 3rd J, Gentile F . 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 143(5):e72-e227. DOI: 10.1161/CIR.0000000000000923. View

2.
Steppan J, Barodka V, Berkowitz D, Nyhan D . Vascular stiffness and increased pulse pressure in the aging cardiovascular system. Cardiol Res Pract. 2011; 2011:263585. PMC: 3154449. DOI: 10.4061/2011/263585. View

3.
Jassal D, Tam J, Bhagirath K, Gaboury I, Sochowski R, Dumesnil J . Association of mitral annular calcification and aortic valve morphology: a substudy of the aortic stenosis progression observation measuring effects of rosuvastatin (ASTRONOMER) study. Eur Heart J. 2008; 29(12):1542-7. DOI: 10.1093/eurheartj/ehn172. View

4.
Nishimura R, Vahanian A, Eleid M, Mack M . Mitral valve disease--current management and future challenges. Lancet. 2016; 387(10025):1324-34. DOI: 10.1016/S0140-6736(16)00558-4. View

5.
Eleid M, Foley T, Said S, Pislaru S, Rihal C . Severe Mitral Annular Calcification: Multimodality Imaging for Therapeutic Strategies and Interventions. JACC Cardiovasc Imaging. 2016; 9(11):1318-1337. DOI: 10.1016/j.jcmg.2016.09.001. View